You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

52 Results
Guidelines and Advice
Updated
Jan 2026
Guidelines and Advice
May 2019
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Guidelines and Advice
Updated
Jan 2026
Guidelines and Advice
Updated
Jan 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
New
Feb 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
May 2019
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Advanced Malignant Pleural Mesothelioma (MPM)
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Rectal
Intent: Neoadjuvant
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Amyloidosis, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
New Drug Funding Program
    Daratumumab and Bortezomib in combo with Cyclophosphamide and Dexamethasone - Previously Untreated Light Chain (AL) Amyloidosis
Jan 2026

Pages